Benhamou Pierre-Henri

Pédiatrie

Dbv Technologies
Montrouge, France

72 Activités

0 Followers

Scientifique

Digital

Production scientifique

Activités par an

Expertise

Sujets de recherche

Hypersensibilité Hypersensibilité aux arachides Hypersensibilité alimentaire Hypersensibilité au lait Anaphylaxie Hypersensibilité immédiate Coqueluche Gastrite Infections à virus respiratoire syncytial

Collaborateurs

Dupont Christophe

Hôpital Necker Enfants Malades, Paris, France

Martin Laurent

Orphelia Pharma, Paris, France

Kalach Nicolas

Hôpital Saint Vincent de Paul Lille, Lille, France

Pelletier Bertrand

Efs Hdf-norm - Lbm Norm Caen, Caen, France

Industries

Dernières activités

Epicutaneous immunization using synthetic virus-like particles efficiently boosts protective immunity to respiratory syncytial virus.

Vaccine 19 juin 2021

Safety and immunogenicity of the epicutaneous reactivation of pertussis toxin immunity in healthy adults: a phase I, randomized, double-blind, placebo-controlled trial.

Clinical microbiology and infection : the official publication of the European Society of Clinical Microbiology and Infectious Diseases 05 septembre 2020

Viaskin Pertussis Vaccine Trial: A Phase I Dose Escalation Randomized, Double-blind, Placebo-controlled Safety and Immunogenicity Trial of the Reactivation of Pertussis Toxin Immunity With the Viaskin Epicutaneous Delivery System in Healthy Adults

Essai Clinique (DBV Technologies) 28 février 2020

Epicutaneous Tolerance Induction to a Bystander Antigen Abrogates Colitis and Ileitis in Mice.

Inflammatory bowel diseases 14 juin 2018

Treatment of gastric eosinophilia by epicutaneous immunotherapy in piglets sensitized to peanuts.

Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology 20 octobre 2017

Crucial Role of Langerhans Cells in Allergen Uptake and Regulatory T Cell Induction in Epicutaneous Immunotherapy